Bristol Myers Squibb (BMY) Registers a Bigger Fall Than the Market: Important Facts to Note

Bristol Myers Squibb (BMY) ended the recent trading session at $54.62, demonstrating a -1.69% change from the preceding day's closing price. The stock's performance was behind the S&P 500's daily loss of 0.01%. On the other hand, the Dow registered a gain of 0.03%, and the technology-centric Nasdaq increased by 0.17%. The biopharmaceutical company's shares have seen an increase of 2.49% over the last month, surpassing the Medical sector's loss of 1.67% and the S&P 500's gain of 0.78%.The investment community will be paying close attention to the earnings performance of Bristol Myers Squibb in its upcoming release. The company is slated to reveal its earnings on February 5, 2026. The company is predicted to post an EPS of $1.5, indicating a 10.18% decline compared to the equivalent quarter last year. Alongside, our most recent consensus estimate is anticipating revenue of $12.25 billion, indicating a 0.71% downward movement from the same quarter last year. For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $6.4 per share and a revenue of $47.9 billion, representing changes of +456.52% and 0%, respectively, from the prior year. Investors should also take note of any recent adjustments to analyst estimates for Bristol Myers Squibb. These revisions help to show the ever-changing nature of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential. Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system. The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, there's been a 0.26% rise in the Zacks Consensus EPS estimate. Bristol Myers Squibb presently features a Zacks Rank of #3 (Hold). Digging into valuation, Bristol Myers Squibb currently has a Forward P/E ratio of 9.22. This denotes a discount relative to the industry average Forward P/E of 20.16. We can also see that BMY currently has a PEG ratio of 0.17. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. The Medical - Biomedical and Genetics was holding an average PEG ratio of 1.45 at yesterday's closing price. The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 94, putting it in the top 39% of all 250+ industries. The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions. Quantum Computing Stocks Set To SoarArtificial intelligence has already reshaped the investment landscape, and its convergence with quantum computing could lead to the most significant wealth-building opportunities of our time.Today, you have a chance to position your portfolio at the forefront of this technological revolution. In our urgent special report, Beyond AI: The Quantum Leap in Computing Power, you'll discover the little-known stocks we believe will win the quantum computing race and deliver massive gains to early investors.Access the Report Free Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bristol Myers Squibb Company (BMY): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks